Clinical Trials Logo

Heart Failure NYHA Class II clinical trials

View clinical trials related to Heart Failure NYHA Class II.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04862273 Active, not recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis

CMR for CA
Start date: April 1, 2021
Phase:
Study type: Observational

The study aims to test the diagnostic accuracy of native T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that native T1 mapping with a cut-off value of 1341ms (3 tesla CMR) in older patients with symptomatic heart failure, increased LV wall thickness and elevated cardiac biomarkers is non-inferior to the reference method to diagnose cardiac amyloidosis (CA). As secondary measure, a web-based ATTR probability estimator for the diagnosis of CA will be evaluated.

NCT ID: NCT04180696 Active, not recruiting - Heart Failure Clinical Trials

Mid-Q Response Study

Start date: January 23, 2020
Phase: N/A
Study type: Interventional

The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study. The purpose of the Mid-Q Response study is to test the hypothesis that the AdaptivCRT (aCRT) algorithm is superior to standard CRT therapy regarding patient outcomes in CRT indicated patients with moderate QRS duration, preserved atrioventricular (AV) conduction and left bundle branch block (LBBB). The study will be executed at approximately 60 centers in Asia. The subjects will be randomly assigned in a 1:1 ratio to the aCRT ON (Adaptive Bi-V and LV) group or the aCRT OFF (Nonadaptive CRT) group. The primary objective is to test the hypothesis that aCRT ON increases the proportion of patients that improve on the Clinical Composite Score (CCS) compared to aCRT OFF at 6 months of follow-up.